Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis; Novartis Pharmaceuticals
• Treatments: Rivastigmine

Criteria

Inclusion Criteria:

• Diagnosis of dementia of the Alzheimer's type

• Males, and females who are surgically sterile or one year postmenopausal

• A primary caregiver willing to accept responsibility for supervising the treatment

Exclusion Criteria:

• Any condition (other than Alzheimer's) that could explain patient's dementia

• An advanced, severe or unstable disease that may put the patient at special risk

• Current diagnosis of active, uncontrolled seizure disorder or unstable cardiovascular disease